AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that patients in a mid-stage trial of its experimental depression ...
After neoadjuvant breast cancer treatment, axillary radiotherapy may offer an effective alternative to axillary lymph node dissection.
US Food and Drug Administration (FDA) officials credited recent advancements in regulatory science and flexibilities with ...
The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.
The main advantage of proton therapy is its precision. Protons deposit most of their energy directly in the tumor with little ...
Motor function improved with a favorable safety profile for patients with Parkinson’s disease who used tavapadon while receiving oral levodopa, according to a study published in JAMA Neurology.This ...
A remarkable clinical response was achieved in 79% of patients battling drug-resistant, true extramedullary myeloma (EMM) ...
The U.S. Food and Drug Administration (FDA) on Friday concluded that Replimmune Group Inc. REPL Biologics License Application ...
Short children born small for gestational age maintained increases in height velocity and height standard deviation scores at ...
Intermittent tacrolimus after dupilumab discontinuation in patients with AD was associated with longer time to disease flare than on-demand therapy.
Gulf Business on MSN
New weight-loss pill lands in UAE: Here’s what you need to know
Unlike traditional injectable GLP-1 therapies, the drug is a small molecule, non-peptide pill taken once daily, with no restrictions on food, water, or timing ...
Late breaking results from the phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate non inferiority to paclitaxel/carboplatin followed by letrozole (PC/L) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results